JP2022519750A5 - - Google Patents

Info

Publication number
JP2022519750A5
JP2022519750A5 JP2021546388A JP2021546388A JP2022519750A5 JP 2022519750 A5 JP2022519750 A5 JP 2022519750A5 JP 2021546388 A JP2021546388 A JP 2021546388A JP 2021546388 A JP2021546388 A JP 2021546388A JP 2022519750 A5 JP2022519750 A5 JP 2022519750A5
Authority
JP
Japan
Prior art keywords
item
sequence
sequence number
nucleic acid
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021546388A
Other languages
English (en)
Japanese (ja)
Other versions
JP7562544B2 (ja
JP2022519750A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/017292 external-priority patent/WO2020163761A1/en
Publication of JP2022519750A publication Critical patent/JP2022519750A/ja
Publication of JP2022519750A5 publication Critical patent/JP2022519750A5/ja
Priority to JP2024165838A priority Critical patent/JP7778879B2/ja
Application granted granted Critical
Publication of JP7562544B2 publication Critical patent/JP7562544B2/ja
Priority to JP2025199231A priority patent/JP2026020285A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021546388A 2019-02-08 2020-02-07 ミオシン15プロモーター及びその使用 Active JP7562544B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024165838A JP7778879B2 (ja) 2019-02-08 2024-09-25 ミオシン15プロモーター及びその使用
JP2025199231A JP2026020285A (ja) 2019-02-08 2025-11-19 ミオシン15プロモーター及びその使用

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962802874P 2019-02-08 2019-02-08
US62/802,874 2019-02-08
US201962928311P 2019-10-30 2019-10-30
US62/928,311 2019-10-30
US202062965773P 2020-01-24 2020-01-24
US62/965,773 2020-01-24
PCT/US2020/017292 WO2020163761A1 (en) 2019-02-08 2020-02-07 Myosin 15 promoters and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024165838A Division JP7778879B2 (ja) 2019-02-08 2024-09-25 ミオシン15プロモーター及びその使用

Publications (3)

Publication Number Publication Date
JP2022519750A JP2022519750A (ja) 2022-03-24
JP2022519750A5 true JP2022519750A5 (https=) 2023-02-14
JP7562544B2 JP7562544B2 (ja) 2024-10-07

Family

ID=71947522

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021546388A Active JP7562544B2 (ja) 2019-02-08 2020-02-07 ミオシン15プロモーター及びその使用
JP2024165838A Active JP7778879B2 (ja) 2019-02-08 2024-09-25 ミオシン15プロモーター及びその使用
JP2025199231A Pending JP2026020285A (ja) 2019-02-08 2025-11-19 ミオシン15プロモーター及びその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024165838A Active JP7778879B2 (ja) 2019-02-08 2024-09-25 ミオシン15プロモーター及びその使用
JP2025199231A Pending JP2026020285A (ja) 2019-02-08 2025-11-19 ミオシン15プロモーター及びその使用

Country Status (7)

Country Link
US (2) US12252520B2 (https=)
EP (1) EP3920974A4 (https=)
JP (3) JP7562544B2 (https=)
CN (3) CN119307494A (https=)
AU (1) AU2020218547A1 (https=)
CA (1) CA3129422A1 (https=)
WO (1) WO2020163761A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112703016B (zh) 2018-04-27 2024-11-22 分贝治疗公司 肌球蛋白15启动子及其用途
US11660353B2 (en) 2018-04-27 2023-05-30 Decibel Therapeutics, Inc. Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems
EP3921032A4 (en) 2019-02-08 2022-11-30 Decibel Therapeutics, Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF SENSORINEURAL HEARING LOSS USING OTOFERLIN DOUBLE VECTOR SYSTEMS
KR20220130093A (ko) * 2019-10-30 2022-09-26 데시벨 테라퓨틱스, 인크. 오토펄린 듀얼 벡터 시스템을 사용한 감각신경성 난청을 치료하기 위한 조성물 및 방법
KR20220157944A (ko) 2020-02-21 2022-11-29 아카우오스, 인크. 인간 대상체에서 비-연령-연관 청각 장애를 치료하기 위한 조성물 및 방법
CN112194717B (zh) * 2020-09-30 2021-12-14 东南大学 一种促进耳蜗毛细胞再生的肽段Tr及其应用
US20250073354A1 (en) 2021-12-23 2025-03-06 University Of Rochester Compositions and methods for delivery of agents to inner ear
EP4452336A2 (en) 2021-12-23 2024-10-30 University of Rochester Csf transport pathway for delivery of agents to inner ear
CN116836975A (zh) * 2022-03-25 2023-10-03 上海玮美基因科技有限责任公司 一种耳蜗和/或前庭细胞特异性启动子及其应用
WO2024250774A1 (zh) * 2023-06-07 2024-12-12 苏州星奥拓维生物技术有限公司 耳蜗外毛细胞特异性启动子及其应用
CN117486995A (zh) * 2023-11-03 2024-02-02 首都医科大学附属北京胸科医院 Kncn蛋白在结核诊断试剂中的应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9720465D0 (en) 1997-09-25 1997-11-26 Oxford Biomedica Ltd Dual-virus vectors
US6436392B1 (en) 1998-05-20 2002-08-20 University Of Iowa Research Foundation Adeno-associated virus vectors
EP1224313A1 (en) 1999-10-07 2002-07-24 University of Iowa Research Foundation Adeno-associated viruses and uses thereof
AU7895700A (en) 1999-10-15 2001-04-30 Dalhousie University Method and vector for producing and transferring trans-spliced peptides
US20040072154A1 (en) * 2000-12-22 2004-04-15 Morris David W. Novel compositions and methods for cancer
JP2003088388A (ja) * 2001-09-14 2003-03-25 Herikkusu Kenkyusho:Kk 新規な全長cDNA
US20060024278A1 (en) * 2004-01-23 2006-02-02 The General Hospital Corporation Methods and products related to the production of inner ear hair cells
US20070161031A1 (en) * 2005-12-16 2007-07-12 The Board Of Trustees Of The Leland Stanford Junior University Functional arrays for high throughput characterization of gene expression regulatory elements
WO2007127428A2 (en) 2006-04-28 2007-11-08 University Of Florida Research Foundation, Inc. Double-stranded/self-complementary vectors with a truncated cba promoter and methods of gene delivery
CN101711164B (zh) 2007-01-18 2014-06-04 密苏里-哥伦比亚大学 可修复肌纤维膜中的神经元型一氧化氮合酶的合成小/微-抗肌萎缩蛋白基因
FR2919305B1 (fr) 2007-07-26 2009-09-18 Genethon Ass Loi De 1901 Vecteurs viraux adeno-associes pour l'expression de la dysferline.
US8188131B2 (en) 2008-02-07 2012-05-29 Massachusetts Eye & Ear Infirmary Compounds that enhance Atoh1 expression
US8236557B2 (en) 2008-05-28 2012-08-07 University Of Missouri-Columbia Hybrid-AAV vectors to deliver large gene expression cassette
WO2010062905A2 (en) 2008-11-26 2010-06-03 The Regents Of The University Of California Lateral ventricle cell compositions and use for treating neural degenerative diseases
SG10201800541SA (en) 2010-04-23 2018-03-28 Univ Florida Raav-guanylate cyclase compositions and methods for treating leber's congenital amaurosis-1 (lca1)
WO2013075008A1 (en) 2011-11-16 2013-05-23 University Of Florida Research Foundation Inc. Aav dual vector systems for gene therapy
BR112014016937A2 (pt) * 2012-01-12 2017-06-13 Quark Pharmaceuticals Inc terapia de combinação para o tratamento de desordens de audição e do equilíbrio
US20150050354A1 (en) * 2012-04-02 2015-02-19 Moderna Therapeutics, Inc. Modified polynucleotides for the treatment of otic diseases and conditions
NZ701693A (en) 2012-04-18 2017-02-24 The Children’S Hospital Of Philadelphia Composition and methods for highly efficient gene transfer using aav capsid variants
US20150209406A1 (en) * 2012-09-07 2015-07-30 Massachusetts Eye And Ear Infirmary Methods and compositions for regenerating hair cells and/or supporting cells
AU2014255665B2 (en) 2013-04-18 2018-08-02 Fondazione Telethon Effective delivery of large genes by dual AAV vectors
EP3492597A3 (en) 2013-05-21 2019-08-28 University of Florida Research Foundation, Inc. Capsid-modified, raav3 vector compositions and methods of use in gene therapy of human liver cancer
EP3258955A1 (en) * 2015-02-20 2017-12-27 Institut Pasteur Prevention and/or treatment of hearing loss or impairment
SI3265571T1 (sl) 2015-03-03 2022-10-28 Fondazione Telethon Več vektorski sistem in njegove uporabe
SG10201913266UA (en) * 2015-12-11 2020-02-27 Massachusetts Eye & Ear Infirmary Materials and methods for delivering nucleic acids to cochlear and vestibular cells
JP7007273B2 (ja) 2015-12-22 2022-01-24 アンセルム(アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル) 遺伝子治療用の改良された複合型二重組換えaavベクターシステム
EP3510161A4 (en) 2016-08-23 2020-04-22 Akouos, Inc. COMPOSITIONS AND METHODS FOR TREATING PERSONAL HEARING LOSS IN A PERSON
WO2018145111A1 (en) 2017-02-06 2018-08-09 Children's Medical Center Corporation Materials and methods for delivering nucleic acids to cochlear and vestibular cells
KR102606810B1 (ko) 2017-05-05 2023-11-27 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 오토펄린을 발현시키기 위한 조성물 및 방법
DE102018103924A1 (de) 2018-02-21 2019-08-22 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Gentherapeutische Behandlung von Schwerhörigkeit
IL325122A (en) 2018-02-22 2026-02-01 Akouos Inc Compositions and methods for treating non-age-related hearing impairment in humans
US11660353B2 (en) * 2018-04-27 2023-05-30 Decibel Therapeutics, Inc. Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems
CN112703016B (zh) * 2018-04-27 2024-11-22 分贝治疗公司 肌球蛋白15启动子及其用途
WO2020093018A1 (en) 2018-11-01 2020-05-07 University Of Florida Research Foundation, Incorporated A codon optimized otoferlin aav dual vector gene therapy
EP4063510A1 (en) 2018-11-07 2022-09-28 Akouos, Inc. Use of adeno-associated viral vectors to correct gene defects/ express proteins in hair cells and supporting cells in the inner ear
EP4295913A3 (en) 2019-01-18 2024-03-06 Institut Pasteur Aav-mediated gene therapy restoring the otoferlin gene
SG11202107645RA (en) 2019-01-18 2021-08-30 Voyager Therapeutics Inc Methods and systems for producing aav particles
EP3921032A4 (en) 2019-02-08 2022-11-30 Decibel Therapeutics, Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF SENSORINEURAL HEARING LOSS USING OTOFERLIN DOUBLE VECTOR SYSTEMS
KR20220130093A (ko) 2019-10-30 2022-09-26 데시벨 테라퓨틱스, 인크. 오토펄린 듀얼 벡터 시스템을 사용한 감각신경성 난청을 치료하기 위한 조성물 및 방법
EP4294460A4 (en) 2021-02-19 2025-06-25 Decibel Therapeutics, Inc. Methods for treating sensorineural hearing loss using otoferlin dual vector systems
IL322655A (en) 2023-02-17 2025-10-01 Decibel Therapeutics Inc Method and compositions for administering a dual autopralin vector system

Similar Documents

Publication Publication Date Title
JP2022519750A5 (https=)
JP2021521842A5 (https=)
US20240131093A1 (en) Compositions and methods of treating huntington's disease
US8257969B2 (en) Genetic suppression and replacement
CA2909733C (en) Effective delivery of large genes by dual aav vectors
JP7577291B6 (ja) Aavカプシド設計
JP2025000750A5 (https=)
US11819478B2 (en) Selective gene therapy expression system
AU2017268382B2 (en) Compositions and methods of treating Huntington's disease
AU2015335923B2 (en) Recombinant AAV variants and uses thereof
JP2021512649A5 (https=)
CN117535350A (zh) 年龄相关疾病和病症的基因治疗方法
CN114072179A (zh) 肌球蛋白15启动子及其用途
CN114945583A (zh) Α-肌聚糖的腺相关病毒载体递送和肌营养不良症的治疗
CN112703016A (zh) 肌球蛋白15启动子及其用途
JP2022539238A5 (https=)
JP2021533801A5 (https=)
KR20250105715A (ko) 근육에서의 유전자 발현을 위한 핵산 조절 요소 및 사용 방법
US20230250422A1 (en) Cpg-free itrs for aav gene therapy
US20250026795A1 (en) Functional aav capsids for intravitreal administration
JP2021513871A (ja) F8遺伝子機能を回復させるためのアデノ随伴ウイルス組成物及びその使用の方法
CN114555800A (zh) 经修饰的神经氨酸酶
CN119220539A (zh) Gjb2启动子序列及其载体和应用
JP2026513145A (ja) 標的遺伝子の発現カセット及びその応用
RU2023131775A (ru) Композиции и способы лечения сенсоневральной тугоухости с применением стереоцилиновых двухвекторных систем